%0 Journal Article
%T rVSVŠ€G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
%A Beth-Ann Coller
%A Brian K. Martin
%A D. Gray Heppner
%A David K. Clarke
%A For the Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)
%A Jakub K. Simon
%A James S. Robertson
%A Jayanthi Wolf
%A Joan Fusco
%A Kayvon Modjarrad
%A Patricia E. Fast
%A Richard Nichols
%A Sean P. Troth
%A Sheri Dubey
%A Thomas P. Monath
%A Vidisha Singh
%J Archive of "Vaccine: X".
%D 2019
%R 10.1016/j.jvacx.2019.100009
%K Vaccines
%K Ebola vaccine
%K Vesicular stomatitis virus vector
%K Viral vector
%K Brighton collaboration
%K Risk/benefit assessment
%K Vaccine safety
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668225/